Literature DB >> 21369876

Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.

Jurgen Bernd Bulitta1, Ayhan Bingölbali, Beom Soo Shin, Cornelia Barbara Landersdorfer.   

Abstract

Mechanistic modeling greatly benefits from automated pre- and post-processing of model code and modeling results. While S-ADAPT provides many state-of-the-art parametric population estimation methods, its pre- and post-processing capabilities are limited. Our objective was to develop a fully automated, open-source pre- and post-processor for nonlinear mixed-effects modeling in S-ADAPT. We developed a new translator tool (SADAPT-TRAN) based on Perl scripts. These scripts (a) automatically translate the core model components into robust Fortran code, (b) perform extensive mutual error checks across all input files and the raw dataset, (c) extend the options of the Monte Carlo Parametric Expectation Maximization (MC-PEM) algorithm, and (d) improve the numerical robustness of the model code. The post-processing scripts automatically summarize the results of one or multiple models as tables and, by generating problem specific R scripts, provide an extended series of standard and covariate-stratified diagnostic plots. The SADAPT-TRAN package substantially improved the efficiency to specify, debug, and evaluate models and enhanced the flexibility of using the MC-PEM algorithm for parallelized estimation in S-ADAPT. The parameter variability model can take any combination of normally, log-normally, or logistically distributed parameters and the SADAPT-TRAN package can automatically generate the Fortran code required to specify between occasion variability. Extended estimation features are available to avoid local minima, estimate means with negligible variances, and estimate variances for fixed means. The SADAPT-TRAN package significantly facilitated model development in S-ADAPT, reduced model specification errors, and provided useful error messages for beginner and advanced users. This benefit was greatest for complex mechanistic models.

Entities:  

Mesh:

Year:  2011        PMID: 21369876      PMCID: PMC3085703          DOI: 10.1208/s12248-011-9257-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  23 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

3.  Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

Authors:  Lars Lindbom; Jakob Ribbing; E Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2004-08       Impact factor: 5.428

4.  Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.

Authors:  Chee M Ng; A Patnaik; M Beeram; C C Lin; C H Takimoto
Journal:  Cancer Chemother Pharmacol       Date:  2010-07-08       Impact factor: 3.333

5.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Development of translational pharmacokinetic-pharmacodynamic models.

Authors:  D E Mager; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  2008-03-26       Impact factor: 6.875

Review 7.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

8.  Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

Authors:  Chee M Ng; Amita Joshi; Russell L Dedrick; Marvin R Garovoy; Robert J Bauer
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

9.  Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.

Authors:  Lu Xu; Julie L Eiseman; Merrill J Egorin; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-06       Impact factor: 2.745

10.  Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability.

Authors:  Ho-Leung Fung; Pei-Suen Tsou; Jurgen B Bulitta; Doanh C Tran; Nathaniel A Page; David Soda; Sun Mi Fung
Journal:  AAPS J       Date:  2008-02-08       Impact factor: 4.009

View more
  64 in total

1.  Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate.

Authors:  Romain Carrez; Julien Brillault; Nicolas Grégoire; Isabelle Lamarche; Julian Laroche; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics.

Authors:  Cornelia B Landersdorfer; Robert L Findling; Jean A Frazier; Vivian Kafantaris; Carl M J Kirkpatrick
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

3.  Controlling antibiotic release from mesoporous silica nano drug carriers via self-assembled polyelectrolyte coating.

Authors:  Tasnuva Tamanna; Jurgen B Bulitta; Aimin Yu
Journal:  J Mater Sci Mater Med       Date:  2015-02-11       Impact factor: 3.896

4.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Authors:  Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis.

Authors:  Pornpan Koomanachai; Cornelia B Landersdorfer; Gong Chen; Hee Ji Lee; Anupop Jitmuang; Somkiat Wasuwattakul; Suchai Sritippayawan; Jian Li; Roger L Nation; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

6.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

7.  Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Authors:  Jürgen B Bulitta; Neang S Ly; Cornelia B Landersdorfer; Nicholin A Wanigaratne; Tony Velkov; Rajbharan Yadav; Antonio Oliver; Lisandra Martin; Beom Soo Shin; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

8.  Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Authors:  N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji
Journal:  Clin Microbiol Infect       Date:  2020-02-12       Impact factor: 8.067

9.  Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

10.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.